Anti-viral prophylaxis in inactive hepatitis B virus carriers with hemato-oncological malignancies who receive chemotherapy

Minerva Gastroenterologica e Dietologica

Volumn 52, Issue 1, 2006, Pages 39-45

  Idilman, R ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Hematological neoplasms; Hepatitis B; Immunosuppression; Lamivudine

Indexed keywords

LAMIVUDINE;

CANCER; CHEMOTHERAPY; DRUG EFFECT; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; REVIEW; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; CARRIER STATE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HUMANS;

EID: 33646340935     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Maddrey WC. Hepatitis B. An important public health issue. J Med Virol 2000;61:362-6.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
3. Ustün C, Koc H, Karayalcin S, Akyol G, Gurman G, Ilhan O et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;20:289-96.
4. Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005;74:158-65.
5. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-9.
6. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995;22:36-43.
7. Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: precore/core mutations may play an important role. J Med Virol 2000;60:249-55.
8. Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. J Med Virol 2000;62:299-307.
9. Xunrong L, Au WY, Liang R, Lau GKK. Hepatitis B virus reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol 2001;11:287-99.
10. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83:1627-31.
11. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: Antiviral efficacy and viral resistance. Am J Gastroenterol 2002;97:1618-28.
12. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
13. Qaqish RB, Mattes KA, Ritchie DJ. Adefovir dipivoxil: A new antiviral agent for the treatment of hepatitis B virus infection. Clin Therap 2003;25:3084-99.
14. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
15. Lim LL, Wai CT, Lee YM, Kong HL, Lim R, Koay E et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002;16:1939-44.
16. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-6.
17. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003;44:759-66.
18. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9.
19. Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepatitis 2004;11:141-7.
20. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-34.
21. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005;55:828-31.
22. Hui CK, Cheung WWW, Au WY, Lie AKW, Zhang HY, Yueng YH et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with hematological malignancy on completion of cytotoxic chemotherapy. Gut 2005;54:1597-603.
23. Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus infected patients treated for non-Hodgkin's lymphoma. Blood 2002;99:724-5.
24. Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005;42:813-9.
25. Lau GKK, Liang R, Wu PC, Lee CK, Lim WL, Au WY. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 1998;28:359-68.
26. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preempitive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma. Ann Hematol 2004;83:270-5.
27. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B infection. Am J Gastroenterol 1999;94:249-51.
28. Uchida N, Gondo H, Himeji D, Kaji Y, Sata M, Niho Y. Lamivudine therapy for a hepatitis B surface antigen positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2000;26:1243-5.
29. Cainelli F, Longhi MS, Concia E, Vento S. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 2001;96:1651-2.
30. Chan TM, Fang GX, Tang CSO, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV-DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002;36:1246-52.
31. Lau GKK, He M, Fong DYT, Bartholomeusz A, Au WY, Lie AK et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-9.